Perspectives:

High-Grade Prostate Cancer and the Prostate Cancer Prevention Trial

Christopher J. Logothetis and Paul F. Schellhammer
Cancer Prev Res 2008 1: 151-152. Published Online First May 18, 2008. doi: 10.1158/1940-6207.CAPR-08-0085 [Full Text] [PDF] [Related Articles]  

Targeting Transcription Factors for Cancer Prevention—the Case of Nrf2

Nancy H. Colburn and Thomas W. Kensler
Cancer Prev Res 2008 1: 153-155. Published Online First March 31, 2008. doi: 10.1158/1940-6207.CAPR-08-0025 [Full Text] [PDF] [Related Article]  

Deregulated EGFR Signaling during Lung Cancer Progression: Mutations, Amplicons, and Autocrine Loops

Adi F. Gazdar and John D. Minna
Cancer Prev Res 2008 1: 156-160. doi: 10.1158/1940-6207.CAPR-08-0080 [Full Text] [PDF] [Related Articles]  

Commentary:

The Untapped Potential of Genetically Engineered Mouse Models in Chemoprevention Research: Opportunities and Challenges

Cory Abate-Shen, Powel H. Brown, Nancy H. Colburn, Eugene W. Gerner, Jeffery E. Green, Martin Lipkin, William G. Nelson, and David Threadgill
Cancer Prev Res 2008 1: 161-166. doi: 10.1158/1940-6207.CAPR-08-0076 [Abstract] [Full Text] [PDF]  

Research Articles:

Pathologic Characteristics of Cancers Detected in the Prostate Cancer Prevention Trial: Implications for Prostate Cancer Detection and Chemoprevention

M. Scott Lucia, Amy K. Darke, Phyllis J. Goodman, Francisco G. La Rosa, Howard L. Parnes, Leslie G. Ford, Charles A. Coltman, Jr., and Ian M. Thompson
Cancer Prev Res 2008 1: 167-173. Published Online First May 18, 2008. doi: 10.1158/1940-6207.CAPR-08-0078 [Abstract] [Full Text] [PDF] [Perspective on This Article][Finasteride and Prostate Cancer: New York Times Article]  

Finasteride Does Not Increase the Risk of High-Grade Prostate Cancer: A Bias-Adjusted Modeling Approach

Mary W. Redman, Catherine M. Tangen, Phyllis J. Goodman, M. Scott Lucia, Charles A. Coltman, Jr., and Ian M. Thompson
Cancer Prev Res 2008 1: 174-181. Published Online First May 18, 2008. doi: 10.1158/1940-6207.CAPR-08-0092 [Abstract] [Full Text] [PDF] [Perspective on This Article][Finasteride and Prostate Cancer: New York Times Article]  

Estimating Rates of True High-Grade Disease in the Prostate Cancer Prevention Trial

Paul Pinsky, Howard Parnes, and Leslie Ford
Cancer Prev Res 2008 1: 182-186. Published Online First May 18, 2008. doi: 10.1158/1940-6207.CAPR-07-0007 [Abstract] [Full Text] [PDF] [Perspective on This Article][Finasteride and Prostate Cancer: New York Times Article]  

Increased Susceptibility of Nrf2 Knockout Mice to Colitis-Associated Colorectal Cancer

Tin Oo Khor, Mou-Tuan Huang, Auemduan Prawan, Yue Liu, Xingpei Hao, Siwang Yu, William Ka Lung Cheung, Jefferson Y. Chan, Bandaru S. Reddy, Chung S. Yang, and Ah-Ng Kong
Cancer Prev Res 2008 1: 187-191. Published Online First March 31, 2008. doi: 10.1158/1940-6207.CAPR-08-0028 [Abstract] [Full Text] [PDF] [Perspective on This Article]  

Epidermal Growth Factor Receptor Abnormalities in the Pathogenesis and Progression of Lung Adenocarcinomas

Ximing Tang, Marileila Varella-Garcia, Ana C. Xavier, Erminia Massarelli, Natalie Ozburn, Cesar Moran, and Ignacio I. Wistuba
Cancer Prev Res 2008 1: 192-200. doi: 10.1158/1940-6207.CAPR-08-0032 [Abstract] [Full Text] [PDF] [Perspective on this Article]  

Intratumoral Epiregulin Is a Marker of Advanced Disease in Non–Small Cell Lung Cancer Patients and Confers Invasive Properties on EGFR-Mutant Cells

Jie Zhang, Kentaro Iwanaga, Kuicheon C. Choi, Marie Wislez, Maria Gabriela Raso, Wei Wei, Ignacio I. Wistuba, and Jonathan M. Kurie
Cancer Prev Res 2008 1: 201-207. Published Online First March 31, 2008. doi: 10.1158/1940-6207.CAPR-08-0014 [Abstract] [Full Text] [PDF] [Perspective on this Article]  

Combination Chemoprevention of HER2/neu-Induced Breast Cancer Using a Cyclooxygenase-2 Inhibitor and a Retinoid X Receptor–Selective Retinoid

Powel H. Brown, Kotha Subbaramaiah, Amoi P. Salmon, Rebecca Baker, Robert A. Newman, Peiying Yang, Xi Kathy Zhou, Reid P. Bissonnette, Andrew J. Dannenberg, and Louise R. Howe
Cancer Prev Res 2008 1: 208-214. doi: 10.1158/1940-6207.CAPR-08-0021 [Abstract] [Full Text] [PDF]  

Letters to the Editor:

Comment re: "Sporadic Aberrant Crypt Foci Are Not a Surrogate Endpoint for Colorectal Adenoma Prevention" and "Aberrant Crypt Foci in the Adenoma Prevention with Celecoxib Trial"

Richard G. Stevens, Theresa P. Pretlow, D. Paul Hurlstone, Charles Giardina, and Daniel W. Rosenberg
Cancer Prev Res 2008 1: 215-216. doi: 10.1158/1940-6207.CAPR-08-0094 [Full Text] [PDF]  

Comment re: "Sporadic Aberrant Crypt Foci Are Not a Surrogate Endpoint for Colorectal Adenoma Prevention" and "Aberrant Crypt Foci in the Adenoma Prevention with Celecoxib Trial"

Peter Lance and Stanley R. Hamilton
Cancer Prev Res 2008 1: 216. doi: 10.1158/1940-6207.CAPR-08-0132 [Full Text] [PDF]  

Comment re: "Sporadic Aberrant Crypt Foci Are Not a Surrogate Endpoint for Colorectal Adenoma Prevention" and "Aberrant Crypt Foci in the Adenoma Prevention with Celecoxib Trial"

Ann G. Zauber, Monica M. Bertagnolli, and for the APC Trial Investigators
Cancer Prev Res 2008 1: 216. doi: 10.1158/1940-6207.CAPR-08-0131 [Full Text] [PDF]  

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.